SCHEMBL282278

SCHEMBL282278

O=C(O)c1nc(O)c2ccc(F)cc2n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 8/20 0.40
KMO O15229 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 1/20 0.39
MAP2K4 P45985 1/20 0.39
MAPK6 Q16659 1/20 0.39
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MPO P05164 1/20 0.37
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
BCKDK O14874 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL281875 0.80 CHEK1 (0.42) KDM4EMAPK1ALDH1A1GAAHPGD
SCHEMBL13099484 0.80 POLB (0.45) DHODHKMOMAP2K4ALDH1A1HPGD
SCHEMBL282186 0.80 KDM4E (0.44) DHODHKMOKDM4EMAPK1MAP2K4
SCHEMBL164797 0.78 TSHR (0.53) KDM4EALDH1A1GAAHPGDMEN1
SCHEMBL20352579 0.77 SMN1; SMN2 (0.47) DHODHKDM4EMAPK1ALDH1A1
SCHEMBL2536405 0.77 KDM4E (0.46) DHODHKDM4EMPOMEN1KMT2A
SCHEMBL2909106 0.77 IGFBP5 (0.45) DHODHKDM4EALDH1A1GAACSNK2A2
SCHEMBL15502381 0.74 NPC1 (0.46) KDM4EMPOKMT2A
SCHEMBL30294150 0.74 MPO (0.46) KDM4EMPOKMT2A
SCHEMBL3267043 0.74 MPO (0.46) KDM4EALDH1A1GAAHSD17B10MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
EP-2428506-B1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) 2014-03-05 EP disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 EP disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed
CN-101671301-A Heterocyclic substituent acardite derivate and application thereof JIANGSU PROVINCIAL INST OF MAT 2010-03-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 DHODH 63/4885KMO 264/4885KDM4E 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.